COPENHAGEN (Reuters) -Denmark’s Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.

Novo Nordisk last week launched a rival bid for obesity biotech Metsera, exceeding an offer from Pfizer as the drugmakers jostled for advantage in the highly lucrative market for weight-loss medications.

Pfizer in turn filed a lawsuit on Friday alleging breach of merger agreement obligations.

Novo Nordisk said it adhered to all the Pfizer merger agreement restrictions.

“This is an intensely competitive space, with at least a dozen other products being developed by major pharma companies. We are confident this transaction does not raise any antitrust issues,” Novo said in an email statement.

Novo Nordisk, the company behin

See Full Page